Abstract
Radiation-induced organised pneumonia may be associated with monoallelic ATM gene mutation http://ow.ly/WIpFe
To the Editor:
Organising pneumonia is defined by the presence of intra-alveolar buds consisting of inflammatory cells, fibroblasts and myofibroblasts, and loose connective tissue, often associated with bronchiolitis obliterans. Organising pneumonia may be cryptogenic (idiopathic) or associated with a variety of causes including, especially, infection, adverse reaction to drugs, connective tissue diseases [1] and radiation therapy to the breast [2, 3].
Ataxia telangiectasia is an autosomal recessive disorder resulting from mutations in the ATM (ataxia telangiectasia mutated) gene located in 11q22.3, with a prevalence of about one in 100 000 children. ATM encodes a 350-kDa protein kinase (3056 aminoacyl residues) with catalytic functions similar to phosphatidylinositol 3′-kinases. After DNA damage, especially DNA double-strand breaks, ATM phosphorylates a thousand targets, activating cell cycle checkpoints, DNA repair, and metabolic and senescence pathways. Ataxia telangiectasia is characterised by neurological manifestations, an increased risk of infections, and cancers, especially lymphomas and leukaemias. Ataxia telangiectasia children affected with cancer present with a severe radiosensitivity if radiation is not reduced. Women carrying a monoallelic ATM mutation, for example, the relatives of ataxia telangiectasia-affected children, are at increased risk of breast cancer [4]. The relative risk of breast cancer at age 50 years in ATM carriers has been estimated to be 4.94 (95% CI 1.90–12.9) among relatives of ataxia telangiectasia patients [5].
A 68-year-old woman underwent tumourectomy for invasive ductal carcinoma of the left breast followed by radiation therapy, completed in September 2008. There were no acute side-effects. The patient did not receive chemotherapy. 2 months later, she developed bilateral pulmonary alveolar opacities on imaging, typical of radiation-induced organising pneumonia (RIOP). She declined bronchoalveolar lavage. She received 40 mg prednisone per day, which was progressively decreased, with regression of the pulmonary opacities. However, relapse occurred in March 2009 while she was taking 5 mg prednisone per day. Prednisone was re-escalated to 30 mg per day, with clearing of the pulmonary opacities. Prednisone was then progressively decreased and eventually discontinued in September 2009.
The patient continued to do well and chest high-resolution computed tomography (HRCT) in February 2012 was normal. However, in September 2012, she presented with dyspnoea on exertion, dry cough and asthenia. HRCT showed reappearance of bilateral alveolar opacities (figure 1). Corticosteroid treatment was reinitiated at a dose of 60 mg per day and then progressively decreased. A daily dose of 30 mg prednisone was required to obtain clearing of alveolar opacities and the dose was again progressively decreased.
Another relapse occurred in May 2013 while under 15 mg prednisone per day. After a transient increase of corticosteroid dose to 20 mg per day, treatment was progressively decreased to 10 mg per day, which was maintained over the long term. In April 2014, the chest radiograph was normal. It was then decided to limit further chest imaging because of the presumed risk of radiation-induced cancer.
The patient had two daughters and one son. Her older daughter was healthy. Her younger daughter and her son were affected with ataxia telangiectasia. Her daughter presented with a severe cerebellar syndrome and no clinical immune deficiency. Lymphocyte counts, and IgG2, IgG4 and IgA serum levels were normal. Lymphocyte karyotype was typical of ataxia telangiectasia with 37% of metaphases presenting with rearrangements of chromosomes 7 and 14. The serum level of α-fetoprotein was very elevated (40 times higher than upper limit of normal). At age 22 years, she developed thyroid carcinoma. She died at the age of 30 years from inhalation pneumonitis and Pseudomonas septicaemia. Her son had cerebellar syndrome, developed T-cell prolymphocytic leukaemia at age 29 years and died a few months later. The diagnosis of ataxia telangiectasia in the daughter and son was based on cerebellar syndrome, biological immune deficiency, increased α-fetoprotein serum level and lymphocyte chromosomal rearrangements of the immunoglobulin superfamily genes. It was confirmed by molecular analysis of the ATM gene.
Sequencing of the ATM gene in the patient's ataxia telangiectasia-affected daughter disclosed two inactivating mutations, c.2734C>T;p.Gln912* and c.8494C>T;p.Arg2832Cys [6]. The patient carried the c.2734C>T;p.Gln912* mutation. The father of the affected children carried the c.8494C>T;p.Arg2832Cys mutation, thus confirming that the two mutations were in two different alleles and that the affected daughter was a compound heterozygote. No ATM test has been performed in the son who died or in the unaffected daughter, who declined the test.
RIOP is an archetypal model of organising pneumonia, quite similar to cryptogenic organising pneumonia and very different from acute radiation pneumonitis following cancer radiotherapy, which develops during or early after completion of radiation therapy, with lesions limited to the irradiated area, eventually resulting in persisting fibrosis. In contrast, RIOP has been defined as occurring within 12 months after radiation therapy, general and/or respiratory symptoms lasting for ≥2 weeks, radiographic lung infiltrates outside the radiation field (abscopal or distant bystander effect) and no evidence of another specific cause [3]. The prevalence of RIOP ranges from 0.8% to 2.9% of patients treated with radiation therapy to the breast (1.68% in an extensive literature review) [7]. Age ≥50 years, concurrent anti-oestrogen therapy [8] and possibly tobacco smoking [7], but not the type of breast surgery (radical or limited), may be associated with an increased risk of RIOP. Patients with RIOP frequently present with fever, cough and dyspnoea, although some may be asymptomatic. Alveolar opacities (often with air bronchogram and migratory) are found on chest imaging [3], with frequent involvement contralateral to the irradiated breast. Most patients receive corticosteroids, with dramatic effects on clinical features and imaging abnormalities. However, multiple relapses are common, usually while decreasing the doses of corticosteroids or soon after these are discontinued [1].
Pulmonary manifestations of ataxia telangiectasia [9, 10] include immune dysfunction, leading to recurrent infections of the upper and lower respiratory tract, aspiration as a consequence of dysfunctional swallowing due to neurological deficit, inefficient cough and interstitial lung disease. Interstitial lung disease is present in about 25% of patients with ataxia telangiectasia, with a mean age of onset of 17.5 years. It is characterised by chronic inflammation and lung fibrosis, with a lymphocytic pattern on bronchoalveolar lavage. Treatment with systemic corticosteroids has been associated with clinical and radiographic improvement [11]. No characteristic organising pneumonia has hitherto been reported in ataxia telangiectasia patients.
Patients with ataxia telangiectasia are unusually sensitive to therapeutic doses of ionising radiation (radiosensitivity) and thus, the use of X-rays and HRCT should be limited to the lowest possible dose [9]. The minus alleles of the ATM−111G>A and 126713G>A polymorphisms have been associated with an increased risk of organising pneumonia in patients who have undergone radiotherapy for lung cancer, with hazard ratios of 2.49 (95% CI 1.07–5.8) and 2.47 (95% CI 1.16–5.28), respectively [12]. In a 30-year-old female treated with total body irradiation and allogenic stem-cell transplantation for acute lymphoblastic leukaemia who has developed erythema, skin bullae and erosions, gastric erythema, and retinopathy because of the exceptional degree of radiation-induced toxicity, sequencing of the ATM gene showed a monoallelic nonsense mutation, c.4396C>T;Arg1466* [13].
Our patient presented a similar nonsense mutation leading to a putative truncated protein or even the absence of protein in case of the instability of the truncated mutation induced product. Although a causal relationship cannot be demonstrated, we hypothesise that it may have predisposed to RIOP. It should be noticed that the frequency of ATM mutation carriers among women affected with breast cancer has been estimated to be 2.04% [14], consistent with the frequency of RIOP in women irradiated for breast cancer. It remains to be explored whether ATM gene mutations may be found in other patients with RIOP.
RIOP has hitherto not been reported in ataxia telangiectasia patients or in individuals with monoallelic ATM gene mutations. We consider that RIOP in our patient may have resulted from the radiosensitivity associated with the ATM gene monoallelic mutation.
Footnotes
Conflict of interest: None declared.
- Received November 6, 2015.
- Accepted December 15, 2015.
- Copyright ©ERS 2016